Market Cap 12.41M
Revenue (ttm) 3.43M
Net Income (ttm) -6.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -203.79%
Debt to Equity Ratio 0.00
Volume 48,512
Avg Vol 1,681,914
Day's Range N/A - N/A
Shares Out 4.36M
Stochastic %K 10%
Beta 0.15
Analysts Hold
Price Target N/A

Company Profile

BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic...

Industry: Asset Management
Sector: Financial Services
Phone: 631 240 8800
Fax: 631 240 8900
Website: www.bnbx.io
Address:
50 Health Sciences Drive, Stony Brook, United States
PapixChulo
PapixChulo Apr. 29 at 1:24 AM
0 · Reply
boomshiva
boomshiva Apr. 28 at 12:28 AM
$BNBX RS approval meeting tomorrow...........will they pluck a rabbit out of a hat?
1 · Reply
5h6rgrff
5h6rgrff Apr. 27 at 10:06 AM
1 · Reply
focafoca99
focafoca99 Apr. 23 at 6:13 PM
$BNBX said LineaRx completed its largest order ever at $1.2 million, with record production cadence, higher margins and zero batch failures. https://www.rapidticker.com/news/bnbx-bnb-plus-corp-completes-historic-2c2a57
0 · Reply
B2iDigital
B2iDigital Apr. 23 at 5:52 PM
BNB Plus Corp. (Nasdaq: $BNBX ) announced that its biopharmaceutical subsidiary, LineaRx, Inc., has completed production of its $1.2 million LineaDNA order, the largest in LineaRx history, with shipments completing in early May 2026. BNB Plus Corp. (Nasdaq: BNBX) is a B2i Digital Featured Company. See the comprehensive profile at https://b2idigital.com/bnbx. The order was produced at historically higher margins with zero batch failures. LineaRx achieved a production cadence of more than 1.5 grams per week during fulfillment, a new record for the company and a further demonstration of the LineaDNA platform’s scalability and manufacturing maturity. “The successful completion of our largest LineaDNA order to date represents a meaningful milestone for LineaRx and for BNB Plus,” said Clay Shorrock, President and Chief Executive Officer of BNB Plus. “LineaDNA continues to demonstrate proven demand from leading genetic medicine and in vitro diagnostic developers. Our ability to consistently execute at scale underscores the strength and commercial readiness of the platform.” As previously announced on April 20, 2026, the Company’s Board of Directors authorized a formal review of strategic alternatives to maximize shareholder value. “As we continue our strategic alternatives review, we expect the compelling fundamentals of the LineaRx business will be central to our evaluation,” continued Shorrock. Read the full press release: https://www.businesswire.com/news/home/20260423790667/en/ LineaDNA is LineaRx’s proprietary cell-free DNA production platform, generating high-fidelity DNA under RUO, GLP, and GMP quality standards. BNB Plus Corp. is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman, CFA as Chief Investment Officer; Joshua Kruger, as Chairman of the Board; and JR Pasch, as Strategic Advisor. To learn more about BNB Plus Corp., visit https://investors.adnas.com. For investor inquiries, contact John Ragozzino Jr., CFA at [email protected]. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
1 · Reply
Marktraderly
Marktraderly Apr. 21 at 9:45 PM
$BNBX bye scam, .25c then delist
1 · Reply
DayTrade_4Life
DayTrade_4Life Apr. 20 at 10:33 PM
🔥Final Tally for the Day. From the WL & Alerts 20 April: 💪Many opportunities for Profits. 👉1 or 2 of these trades more than pays to Join Us. 🆓3 Day FREE Trial & Sale Going On. See Profile. FCHL: .50 to 1.01 (150%) MAAS: $10 to 20.89 (108%) PBM: 10.60 to 19.83 (87%) CMND: .85 to 1.53 (80%) ENVB: 3.20 to 5.43 (69%) - FGI: 7 to 11.48 (64%) $WLDS: 2.10 to 3.24 (54%) - JTAI: 8.60 to 12.98 (50%) ARTL: 5.60 to 7.75 (38%) $BNBX: .73 to .98 (34%) $AVEX: 33.50 to 40.25 (20%) $TOVX: .46 to .54 (17%) $ATAI: 4.75 to 5.50 (15%)
1 · Reply
jcichra
jcichra Apr. 20 at 7:46 PM
$BNBX today's news is just an update on the 3/24 same news... They timely requested an appeal, and that the Treasury has 12.2 million as of 4/18. Meeting on 4/28. Hopefully they have the real pump news in the works since it's been over 3 weeks since the original deficiency letter... The abnormal higher volume/price action this past week implies something is coming
2 · Reply
Marktraderly
Marktraderly Apr. 20 at 7:19 PM
$GMEX dilution scam $BNBX dilution scam careful
0 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Apr. 20 at 6:35 PM
$BNBX biggest scam in the market. R/s after r/s and they have no intention of returning any shareholder value.
2 · Reply
Latest News on BNBX
BNB Plus Transcript: EGM 2026

Apr 28, 2026, 11:00 AM EDT - 16 hours ago

BNB Plus Transcript: EGM 2026


BNB Plus Transcript: Fintech & DATS Investor Conference

Feb 4, 2026, 11:30 AM EST - 2 months ago

BNB Plus Transcript: Fintech & DATS Investor Conference


BNB Plus Provides BNB Treasury and Operational Updates

Dec 9, 2025, 8:00 AM EST - 5 months ago

BNB Plus Provides BNB Treasury and Operational Updates


Applied DNA Reports Third Quarter Fiscal 2025 Financial Results

Aug 14, 2025, 4:10 PM EDT - 9 months ago

Applied DNA Reports Third Quarter Fiscal 2025 Financial Results


BNB Plus Earnings Call Transcript: Q1 2025

Feb 13, 2025, 4:30 PM EST - 1 year ago

BNB Plus Earnings Call Transcript: Q1 2025


BNB Plus Earnings Call Transcript: Q3 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

BNB Plus Earnings Call Transcript: Q3 2024


BNB Plus Earnings Call Transcript: Q1 2024

Feb 8, 2024, 4:30 PM EST - 2 years ago

BNB Plus Earnings Call Transcript: Q1 2024


BNB Plus Earnings Call Transcript: Q4 2023

Dec 7, 2023, 4:30 PM EST - 2 years ago

BNB Plus Earnings Call Transcript: Q4 2023


BNB Plus Earnings Call Transcript: Q3 2023

Aug 10, 2023, 4:30 PM EDT - 2 years ago

BNB Plus Earnings Call Transcript: Q3 2023


BNB Plus Earnings Call Transcript: Q2 2023

May 11, 2023, 4:30 PM EDT - 3 years ago

BNB Plus Earnings Call Transcript: Q2 2023


BNB Plus Earnings Call Transcript: Q1 2023

Feb 9, 2023, 4:30 PM EST - 3 years ago

BNB Plus Earnings Call Transcript: Q1 2023


BNB Plus Earnings Call Transcript: Q4 2022

Dec 14, 2022, 4:30 PM EST - 3 years ago

BNB Plus Earnings Call Transcript: Q4 2022


PapixChulo
PapixChulo Apr. 29 at 1:24 AM
0 · Reply
boomshiva
boomshiva Apr. 28 at 12:28 AM
$BNBX RS approval meeting tomorrow...........will they pluck a rabbit out of a hat?
1 · Reply
5h6rgrff
5h6rgrff Apr. 27 at 10:06 AM
1 · Reply
focafoca99
focafoca99 Apr. 23 at 6:13 PM
$BNBX said LineaRx completed its largest order ever at $1.2 million, with record production cadence, higher margins and zero batch failures. https://www.rapidticker.com/news/bnbx-bnb-plus-corp-completes-historic-2c2a57
0 · Reply
B2iDigital
B2iDigital Apr. 23 at 5:52 PM
BNB Plus Corp. (Nasdaq: $BNBX ) announced that its biopharmaceutical subsidiary, LineaRx, Inc., has completed production of its $1.2 million LineaDNA order, the largest in LineaRx history, with shipments completing in early May 2026. BNB Plus Corp. (Nasdaq: BNBX) is a B2i Digital Featured Company. See the comprehensive profile at https://b2idigital.com/bnbx. The order was produced at historically higher margins with zero batch failures. LineaRx achieved a production cadence of more than 1.5 grams per week during fulfillment, a new record for the company and a further demonstration of the LineaDNA platform’s scalability and manufacturing maturity. “The successful completion of our largest LineaDNA order to date represents a meaningful milestone for LineaRx and for BNB Plus,” said Clay Shorrock, President and Chief Executive Officer of BNB Plus. “LineaDNA continues to demonstrate proven demand from leading genetic medicine and in vitro diagnostic developers. Our ability to consistently execute at scale underscores the strength and commercial readiness of the platform.” As previously announced on April 20, 2026, the Company’s Board of Directors authorized a formal review of strategic alternatives to maximize shareholder value. “As we continue our strategic alternatives review, we expect the compelling fundamentals of the LineaRx business will be central to our evaluation,” continued Shorrock. Read the full press release: https://www.businesswire.com/news/home/20260423790667/en/ LineaDNA is LineaRx’s proprietary cell-free DNA production platform, generating high-fidelity DNA under RUO, GLP, and GMP quality standards. BNB Plus Corp. is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman, CFA as Chief Investment Officer; Joshua Kruger, as Chairman of the Board; and JR Pasch, as Strategic Advisor. To learn more about BNB Plus Corp., visit https://investors.adnas.com. For investor inquiries, contact John Ragozzino Jr., CFA at [email protected]. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
1 · Reply
Marktraderly
Marktraderly Apr. 21 at 9:45 PM
$BNBX bye scam, .25c then delist
1 · Reply
DayTrade_4Life
DayTrade_4Life Apr. 20 at 10:33 PM
🔥Final Tally for the Day. From the WL & Alerts 20 April: 💪Many opportunities for Profits. 👉1 or 2 of these trades more than pays to Join Us. 🆓3 Day FREE Trial & Sale Going On. See Profile. FCHL: .50 to 1.01 (150%) MAAS: $10 to 20.89 (108%) PBM: 10.60 to 19.83 (87%) CMND: .85 to 1.53 (80%) ENVB: 3.20 to 5.43 (69%) - FGI: 7 to 11.48 (64%) $WLDS: 2.10 to 3.24 (54%) - JTAI: 8.60 to 12.98 (50%) ARTL: 5.60 to 7.75 (38%) $BNBX: .73 to .98 (34%) $AVEX: 33.50 to 40.25 (20%) $TOVX: .46 to .54 (17%) $ATAI: 4.75 to 5.50 (15%)
1 · Reply
jcichra
jcichra Apr. 20 at 7:46 PM
$BNBX today's news is just an update on the 3/24 same news... They timely requested an appeal, and that the Treasury has 12.2 million as of 4/18. Meeting on 4/28. Hopefully they have the real pump news in the works since it's been over 3 weeks since the original deficiency letter... The abnormal higher volume/price action this past week implies something is coming
2 · Reply
Marktraderly
Marktraderly Apr. 20 at 7:19 PM
$GMEX dilution scam $BNBX dilution scam careful
0 · Reply
Fast_Eddie_Felson
Fast_Eddie_Felson Apr. 20 at 6:35 PM
$BNBX biggest scam in the market. R/s after r/s and they have no intention of returning any shareholder value.
2 · Reply
Marktraderly
Marktraderly Apr. 20 at 6:30 PM
$BNBX so basically this one has to reclaim 1$ soon or they will be delisted.
0 · Reply
LHTOP
LHTOP Apr. 20 at 4:27 PM
$BNBX Potential high-risk bottom play here. Company appealing NASDAQ dismissal and are unable to do RS. Company exploring AI/GPU options for a quick stock price turn around. Need to watch dilution, but with inability for RS they cannot go too far. Might be worth taking a small position to see if she flies .
0 · Reply
DayTrade_4Life
DayTrade_4Life Apr. 20 at 4:04 PM
🏆FROM THE WL & ALERTS SO FAR TODAY 20 April 26: 💪Brand new member made $600 today before 9:30 open. You can Make Profits too. 👀Join Us. See Profile for info. FCHL: .50 to 1.01 (150%) PBM: 10.60 to 19.83 (87%) CMND: .85 to 1.53 (80%) ENVB: 3.20 to 5.43 (69%) WLDS: 2.10 to 3.24 (54%) $JTAI: 8.60 to 12.98 (50%) $FGI: 7 to 10.39 (48%) $ARTL: 5.60 to 7.75 (38%) $BNBX: .73 to .98 (34%) $TOVX: .46 to .54 (17%) ATAI: 4.75 to 5.50 (15%) AVEX: 33.50 to 38.85 (15%)
1 · Reply
B2iDigital
B2iDigital Apr. 20 at 3:58 PM
BNB Plus Corp. (Nasdaq: $BNBX) announced that its Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value. The Company also provided an update on its Nasdaq listing status. BNB Plus Corp. (Nasdaq: BNBX) is a B2i Digital Featured Company. See the comprehensive profile at https://b2idigital.com/bnbx. Alternatives under consideration include a merger, reverse merger, business combination, acquisition, asset sale, joint venture, additional capital raising transactions, or other strategic transactions. The Company is initially focusing the review on market sectors it believes have potential for high growth, including artificial intelligence infrastructure, digital infrastructure, critical domestic raw materials, defense technologies, and healthcare. Lucid Capital Markets has been retained as financial advisor. In the same announcement, BNBX provided an update on its Nasdaq listing status. On March 20, 2026, the Company received written notice from the Listing Qualifications Department of Nasdaq indicating that it no longer satisfies the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market under Listing Rule 5550(a)(2). Nasdaq determined that the Company is ineligible for a standard compliance period because a reverse stock split was effected within the prior one-year period. The Company timely requested a hearing before the Nasdaq Hearings Panel to address the deficiency, and the common stock will continue to trade on Nasdaq at least through the conclusion of the hearing process. As of 1:00 p.m. ET on April 18, 2026, the Company’s treasury had a value of approximately $12.2 million, representing approximately 3.4x its current market capitalization. BNBX has also recently implemented an active yield generation strategy on its BNB token holdings, intended to potentially grow the BNB token treasury during the strategic review process. “Our Board is committed to maximizing value for our shareholders,” said Clay Shorrock, President and Chief Executive Officer of BNB Plus Corp. “We believe this process will help us assess a range of options available to the Company and determine the most appropriate path forward for the Company and its shareholders.” Read the full press release: https://www.businesswire.com/news/home/20260420345201/en/ BNB Plus unlocks streamlined access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure through a transparent, actively managed BNB treasury. Formerly Applied DNA Sciences, Inc., BNB Plus continues to commercialize its proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. BNB Plus Corp. is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The company’s advisory team includes Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman, CFA as Chief Investment Officer; Josh Kruger, as Chairman of the Board; and JR Pasch, as Strategic Advisor. To learn more about BNB Plus Corp., visit https://investors.adnas.com. For investor inquiries, contact John Ragozzino Jr., CFA at [email protected]. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.
1 · Reply
Marktraderly
Marktraderly Apr. 20 at 3:41 PM
$BYND told ya soooooo fk you shorts!!!! $BNBX go short this scam company!
0 · Reply
mmstk23
mmstk23 Apr. 20 at 3:34 PM
$BNBX Eaten my earned money. Mistake
0 · Reply
jcichra
jcichra Apr. 20 at 3:25 PM
$BNBX 👀👀 last Tuesday it spiked PM... Sold off/sideways during the day, and then spiked harder after the bell at end of day
1 · Reply
Billyhillin
Billyhillin Apr. 20 at 3:25 PM
0 · Reply
mr_bowjangles
mr_bowjangles Apr. 20 at 3:16 PM
0 · Reply
B_Swrrrd
B_Swrrrd Apr. 20 at 2:11 PM
$BNBX Shorts have to cover today. Only A few have so far and it's trying to push. See if it can keep going here.
1 · Reply
DAKZ18
DAKZ18 Apr. 20 at 2:03 PM
$BNBX setting up.
0 · Reply
DAKZ18
DAKZ18 Apr. 20 at 1:51 PM
$BNBX undervalued. And setting up for a squeeze!
0 · Reply